Trial Profile
Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Hodgkin's disease; Kaposi's sarcoma; Liver cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Skin cancer; Solid tumours
- Focus Adverse reactions
- 24 Oct 2023 Results from the expanded Kaposi's-sarcoma cohort (n=32) presented at the 48th European Society for Medical Oncology Congress.
- 13 Oct 2023 Planned End Date changed from 1 Nov 2024 to 11 Oct 2024.
- 25 Mar 2023 Status changed from recruiting to active, no longer recruiting.